ScreenerHero

PTCTPTC Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · ptcbio.com
69.82USD-5.23%Mkt Cap: 5.83B $P/E: —

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. T…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap5.83B $
Enterprise Value6.67B $
Revenue (TTM)1.01B $
Gross Profit1.68B $
Net Income (TTM)682.64M $
Revenue/Share12.35 USD
Last Price69.82 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees991
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)28.21
PEG—
EV/EBITDA38.98
EV/Revenue6.62
P/S5.83
P/B-35.53
EPS (TTM)-0.64
EPS (Forward)2.50
52W Range
47.9451% of range90.86
52W High90.86 USD
52W Low47.94 USD
Profitability
Gross Margin97.28%
Oper. Margin41.32%
EBITDA Margin16.97%
Profit Margin39.44%
ROE-332.49%
ROA23.55%
Growth
Revenue Growth101.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF711.20M $
CapEx (TTM)300.01M $
FCF Margin-28.43%
FCF Yield-4.92%
Net Debt788.82M $
Net Debt/EBITDA4.61
Balance Sheet
Debt/Equity-13.19
Current Ratio3.39
Quick Ratio3.20
Book Value/Sh-1.9850 USD
Cash/Share26.71 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)99.29 USD
Upside (mean)+42.2%
Target Range70.00 USD – 130.00 USD
$70.00+42.2% to mean$130.00
# Analysts14
Ownership
Shares Out.83.46M
Float73.60M
Insiders7.31%
Institutions122.92%
Short Interest
Short Ratio6.0d
Short % Float17.16%
Short % Out.12.66%
Shares Short10.57M
Short (prev mo.)17.32M
Technical
SMA 5077.45 (-9.8%)
SMA 20073.43 (-4.9%)
Beta0.55
S&P 52W Chg18.16%
Avg Vol (30d)1.16M
Avg Vol (10d)882.51K
Technical Indicators
RSI (14)38.8
MACD-1.4891
MACD Signal-1.5904
MACD Hist.+0.1013
BB Upper78.70 USD
BB Middle72.80 USD
BB Lower66.90 USD
BB Width16.21%
ATR (14)2.727 USD
Vol Ratio (20d)0.58x